We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FICO:NYSEFair Isaac Corporation Analysis

Data as of 2026-05-25 - not real-time

$1,239.91

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Fair Isaac posted a **38.7% revenue surge** and lifted its forward EPS to $54.16, underscoring a high‑margin business with operating margins above 58% and a profit margin of 33.7%. The technical picture is mixed: the 20‑day and 50‑day SMAs sit well below the current price of $1,239.91, the MACD is bullish, but the 14‑day RSI at 69 signals the stock is approaching overbought territory and the price sits above the DCF‑derived fair value of $972.24, implying a ~23% premium. A recent short‑seller disclosure by Steve Eisman triggered a 4.8% intraday dip, adding short‑term pressure despite a strong earnings beat and raised guidance.
The valuation therefore leans toward **overvalued** relative to intrinsic estimates, though the PE aligns with the industry average and growth metrics are compelling. Low beta, stable volume, and limited geographic exposure keep systematic risk modest, while regulatory scrutiny of credit‑scoring models adds a medium‑level headwind. Given the strong fundamentals and bullish momentum but elevated price and short‑term sentiment, a cautious hold now with a bias toward buying on any pull‑back is warranted.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • RSI near overbought levels
  • Short‑seller disclosure pressure
  • Price trading above DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust revenue and EPS growth
  • High operating and profit margins
  • Bullish MACD and analyst buy consensus

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Secular demand for analytics and credit‑scoring solutions
  • Recurring subscription revenue from Scores segment
  • Strong cash generation and low leverage relative to equity

Key Metrics & Analysis

Financial Health

Revenue Growth38.70%
Profit Margin33.67%
P/E Ratio39.4
ROA36.92%
P/B Ratio-13.7
Op. Cash Flow$907.3M
Free Cash Flow$730.5M
Industry P/E39.5

Technical Analysis

TrendNeutral
RSI69.2
Support$965.50
Resistance$1,277.23
MA 20$1,103.02
MA 50$1,078.35
MA 200$1,445.89
MACDBullish
VolumeStable
Fear & Greed Index91.71

Valuation

Fair Value$972.24
Target Price$1,531.52
Upside/Downside23.52%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.58
Volatility47.11%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.